Cue Biopharma Inc (CUE) Institutional Ownership & 13F Filings (Q2 2026)

CUE ranks #6166 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CUE is a top-conviction position for Lion Point Capital, LP — at 8.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CUE belongs to Bleichroeder LP, but the position matters far more to Lion Point Capital, LP, who has 8.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

CUE is down 5.2% today, but institutions show net buying of $52.1M this quarter — a divergence between today's price move and the underlying institutional flow.

CUE reported a net loss of $164.1M over the trailing twelve months.

• Not yet profitable — net loss of $164.1M over the trailing twelve months
• Revenue grew 354.4% year over year
• Net income declined year over year, from -$38.9M to -$164.1M
• Operating cash flow was negative, using $21.7M in cash
• Current ratio of 2.74x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.60x equity — within a conventional range